LIXTHIGH SIGNALFINANCIAL10-K

LIXT underwent a massive capital infusion that increased total assets by over 1000% while simultaneously expanding its business scope into proton therapy technology and closing a Phase 2 clinical trial.

The dramatic increase in stockholders' equity from $827K to $9.7M and total assets from $1.1M to $12.7M indicates a major financing event, likely through equity raises or strategic investment. However, the company's operational burn rate has accelerated significantly with net losses nearly doubling, suggesting increased cash requirements for the expanded business operations.

Comparing 2026-03-31 vs 2025-03-24View on EDGAR →
FINANCIAL ANALYSIS

LIXT experienced transformational balance sheet growth with total assets increasing over 1000% to $12.7M and stockholders' equity jumping to $9.7M, indicating substantial new capital infusion. However, operational performance deteriorated significantly with net losses expanding 69% to -$6.1M while R&D expenses actually declined 65%, suggesting the losses stem from other operational areas rather than increased research investment. The combination of massive asset growth with accelerating losses and reduced cash position signals a company in rapid expansion mode but burning through capital at an unsustainable rate.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+1068.3%
$827K$9.7M

Equity base grew 1068.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+1011.6%
$1.1M$12.7M

Asset base grew 1011.6% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+456.8%
$318K$1.8M

Liabilities grew 456.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Assets
Balance Sheet
+352.1%
$1.1M$5.2M

Current assets grew 352.1% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+318.8%
$318K$1.3M

Current liabilities surged 318.8% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-69.5%
-$3.6M-$6.1M

Net income declined 69.5% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
-64.9%
$726K$255K

R&D spending cut 64.9% — could signal cost discipline or concerning reduction in innovation investment.

Interest Expense
P&L
-45.6%
$17K$9K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Income
P&L
-43%
-$3.6M-$5.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-21.5%
$5.4M$4.2M

Cash decreased 21.5% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-24
ADDED
The Company had 11,617,944 shares of common stock issued and outstanding as of March 31, 2026.
The Company is the majority shareholder of Liora Technologies Europe Ltd., which is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers.
Liora s proprietary technology, known as LiGHT System (Linac for Image Guided Hadron Therapy), has significant advantages over currently available technologies for treating tumors with proton therapy.
Liora is an excellent complement to the pharmaceutical side of the Company s business and ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, LB-100 The Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical use.
We expect to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending March 31, 2026.
+7 more — sign up free →
REMOVED
The Company had 2,684,074 shares of common stock issued and outstanding as of March 14, 2025.
The Company believes that the mechanism by which LB-100 affects cancer cell growth is different from cancer agents currently approved for clinical use.
We expect to have data on toxicity and preliminary efficacy from this portion of the clinical trial during the quarter ending December 31, 2025.
As a result, it is uncertain as to whether the Phase 2 portion of this clinical trial will proceed.
- 8 - National Cancer Institute Pharmacologic Clinical Trial In May 2019, the National Cancer Institute (NCI) initiated a glioblastoma (GBM) pharmacologic clinical trial.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →